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ABSTRACT
Basal-like breast cancer is an aggressive tumor subtype with a poor response to 
conventional therapies. Tumor formation and relapse are sustained by a cell subset of 
Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance 
and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-
regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like 
phenotype into luminal. It induces the expression of a functional estrogen receptor 
(ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role 
played by miR-100 in breast cancer free-survival is confirmed by the analysis of a 
cohort of patients’ tumors, which shows that low expression of miR-100 is a negative 
prognostic factor and is associated with gene signatures of high grade undifferentiated 
tumors. Our findings indicate a new possible therapeutic strategy, which could make 
aggressive breast cancers responsive to standard treatments.
INTRODUCTION
The onset and progression of malignant tumors 
depend on a small pool of tumor cells with biological 
properties similar to those of normal adult stem cells. In 
accordance to this cancer stem cell hypothesis, tumors are 
organized in a hierarchical manner and are characterized 
by cells that exhibit the ability to self-renew as well as to 
give rise to differentiated cells. The CSCs represent the 
apex of this hierarchy and appear to be the phenotypic 
and functional equivalents of normal stem cells harboring 
oncogenic mutations [1]. CSCs have been isolated in most 
human solid tumor types, suggesting their central role in 
tumor development, progression and recurrence [2]. The 
presence of a CSC pool is associated with aggressiveness 
and a negative prognosis in breast cancer patients. CSCs 
are thought to possess intrinsic resistance to current 
conventional therapies as compared to the bulk tumor cell 
population and it has been proposed that tumor recurrence 
is driven by this subpopulation of CSCs [3-5]. 
MicroRNAs (miRNAs) are small non-coding RNAs 
that regulate gene expression at a post-transcriptional 
level, thus monitoring several biological processes. Their 
deregulated expression contributes to cancer development 
and progression and can influence both the response to 
therapy [6] and the development of drug resistance [7, 8]. 
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Recently, miRNAs have also emerged as critical players 
in the maintenance of pluripotency, control of self-renewal 
and cell fate [9]. Restricted miRNA patterns are expressed 
only in Embryonic Stem Cells (ESCs) [10, 11] and specific 
miRNAs regulate and are regulated by key stem cell genes 
[12, 13]. The importance of the miRNA pathway in the 
biology of stem cells has been confirmed in Dicer-1 knock-
out mice, where the loss of Dicer-1 results in the depletion 
of the stem cell population in embryos [14]. Moreover, 
Dicer-1 deficient murine ESCs fail to differentiate [15]. 
The majority of miRNAs that are important in ESC 
biology are also involved in oncogenesis. This fuels the 
hypothesis that miRNAs could be determinant in cell 
stemness both in normal and in cancer stem cells [16, 17]. 
In line with this hypothesis, recent data provide evidence 
that miRNAs might connect stemness and metastasis. 
Indeed, some miRNAs specifically expressed in ESCs 
can be inopportunely expressed in cancer cells, promoting 
epithelial mesenchymal transition (EMT) [18, 19] and 
metastasis [20]. 
The miR-100 family of microRNAs is composed 
of three members, miR-100, miR-99a and miR-99b. 
Comparative studies indicate that miR-100 is the oldest 
known animal microRNA [21] and is widely expressed 
in vertebrates [22]. Recent data demonstrated that miR-
100 is under-expressed in human ESCs compared 
to differentiated cells [23] and is required for proper 
differentiation of mouse ESCs [24]. The role of miR-100 
in cancer is quite contradictory, since it can behave either 
as an oncogene or as a tumor suppressor gene, depending 
on the tumor type [25-27]. 
The present work shows that miR-100 plays a 
pivotal role in regulating the transition between stemness 
and differentiation of Breast Cancer Stem Cells (BrCSCs). 
The ectopic expression of miR-100 in CSCs isolated from 
breast cancer specimens impaired their self-renewal and 
tumor-initiating ability. Notably, miR-100 induced luminal 
differentiation in basal-like BrCSCs and rendered them 
sensitive to endocrine therapies, such as tamoxifen and 
fulvestrant. 
RESULTS 
MiR-100 down-regulation induces a 
mammosphere-like phenotype in breast cancer 
cells
Expression profiling studies showed that miR-
100 is deregulated in various types of cancers [25-27]. 
Here, attention was focused on human breast cancer, 
where the biological role of miR-100 in tumor onset and 
progression remains elusive. The aim was to modulate 
miR-100 expression in vitro in breast cancer cells and 
study the biological consequences. The breast cancer 
cell line MCF7 was transiently transfected in the absence 
of serum, either with a miR-100 specific antagomir or 
a control antagomir. MiR-100 antagomir transfected 
cells acquired a mammosphere-like phenotype. These 
mammospheres retained the ability to differentiate when 
cultured in the presence of serum, acquiring an adherent 
shape (Fig. 1A). In order to ensure that antagomir-induced 
mammospheres showed stem cell characteristics, we 
analyzed the expression of the stem cell transcription 
factors Nanog, Oct4 and Sox2. As shown in Fig. 1B, miR-
100 depleted cells expressed higher levels of the three 
transcription factors, compared to cells transfected with 
the control antagomir and to mammospheres obtained 
from MCF7 cells cultured in standard stem cell conditions. 
A wider gene expression analysis revealed that miR-
100 knockdown led to a global gene reprogramming 
that could be responsible for the acquisition of the 
stem-like phenotype (Fig. 1C). Also employed was a 
complementary approach, evaluating miR-100 expression 
in mammospheres generated from breast cancer cell lines 
cultured in standard stem cell conditions. Consistently, the 
expression of the miRNA was lower in mammospheres 
than in the original adherent cells (Supplementary Fig. 1A, 
B). 
Analysis of miR-100 expression in Breast Cancer 
Stem Cells
The level of miR-100 expression might be critical 
in maintaining stemness and in determining the transition 
from a stem to a differentiated status in cancer cells. 
When miR-100 expression was analyzed in a panel of 
CSCs isolated from basal-like and luminal breast cancer 
specimens (Supplementary Table 1), lower average levels 
of miR-100 were found in the CSCs derived from basal-
like tumors (Fig. 2A). BrCSCs derived from patient 5 (P5), 
classified as basal-like subtype and expressing the lowest 
level of miR-100, were selected for further experiments. 
These cells displayed low levels also of the other two 
members of the miR-100 family, namely miR-99a and 
miR-99b (Supplementary Fig. 2A). The expression of the 
miRNAs in P5 BrCSCs was evaluated upon growth in 
conditions which favored differentiation. As shown in Fig. 
2B and Supplementary Fig. 2B, the level of the miRNAs 
promptly increased upon differentiation. 
MiR-100 impairs self-renewing and tumor-
initiating ability of BrCSCs 
In order to investigate whether miR-100 could 
interfere with the stem properties, an exploration of 
the self-renewing ability of tumor-derived P5 BrCSCs 
expressing stable miR-100 upon lentiviral transduction 
(data not shown) was undertaken. BrCSCs infected 
with a short hairpin scramble encoding lentivirus were 
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used as a control. Exogenous expression of miR-100 
severely impaired the clonogenic activity of BrCSCs in 
in vitro limiting dilution assay (Fig. 3A) and in the soft 
agar assay (Fig. 3B). Similar results were observed in the 
subpopulation of BrCSCs obtained by sorting the bulk 
population for the expression of the breast cancer stem 
cell markers CD49f and CD24 [28, 29] (Supplementary 
Fig. 3A, B). The effect of miR-100 on BrCSC proliferation 
was evaluated via a cell cycle analysis. These data showed 
a reduced G2 phase and an enlarged sub-G1 population in 
miRNA transduced BrCSCs as compared to corresponding 
controls (Fig. 3C). Consistently, an increased apoptotic 
rate was revealed by an enhanced caspase3/7 activity 
(Supplementary Fig. 3C). Labeling of BrCSCs with the 
lipophilic fluorescent dye PKH-26 was used to further 
investigate the effect of miR-100 on self-renewal. PKH-
26 is retained by quiescent stem cells whereas it is 
gradually lost by proliferating progenitor cells [30]. MiR-
100 expression reduced the percentage of PKH-26high 
cells (Fig. 3D, E), leading to the depletion of the BrCSC 
proliferating pool.
CSCs are defined as those cells able to originate the 
tumor and recapitulate the heterogeneity of the original 
tumor mass when implanted in immunocompromised 
mice. This inherent tumor-initiating capacity of CSCs is 
believed to be responsible for tumor relapse in patients. 
To address whether miR-100 could affect tumorigenic 
potential, miR-100 or scramble transduced BrCSCs 
were allowed to orthotopically grow in the mouse 
mammary gland of NOD/SCID mice. Interestingly, 
ectopic expression of miR-100 completely suppressed 
tumor growth (Fig. 4A). Histological examination of 
the fat pads showed that only a few breast cancer cells 
expressing the proliferation marker Ki67 and the stem 
cell marker Aldehyde Dehydrogenase 1 (ALDH1) were 
present in the residual tumor xenografts (Fig. 4B). Similar 
results (Supplementary Fig. 4) were obtained in an 
additional patient-derived basal-like BrCSC model (P8, 
Figure 1: MiR-100 inhibition induces a stem-like phenotype in breast cancer cells. A, phase contrast images of MCF7 cells 
transiently transfected with a control (ctr) or a miR-100 specific antagomir (antag). Following miR-100 antagomir transfection, obtained 
mammospheres retained the ability to differentiate when cultured in DMEM 10% Foetal Bovine Serum (antag 10%FBS 24h; antag 10%FBS 
7 days). Magnification 4x. B, stem cell transcription factors expression in control and antagomir transfected cells, analyzed by quantitative 
RT-PCR. Data are average ± SD of biological replicates. MCF7 cells and mammospheres obtained from MCF7 cells upon growth in stem 
cell conditions (MCFS) were used as controls. * P< 0.05. C, stemness and pluripotency gene expression profiling of the cells described in 
(B) performed using TaqMan gene expression arrays. Gene expression is reported as -∆CT (CT gene – CT GAPDH) median-centered. A, 
B, C and D indicate biological replicates. 
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Figure 3: Ectopic expression of miR-100 in BrCSCs impairs self-renewal. A, percentage of clonogenicity in BrCSCs (P5) wild 
type (wt) and stably expressing either a control scramble (scr) or miR-100. Data are average + SD of 3 independent experiments. ** P<0.01. 
B, colony forming efficiency of BrCSCs transduced as in (A), assessed by soft agar assay (bottom); histogram shows the quantitative 
analysis. Data are average + SD of 3 independent experiments. *** P<0.001. C, cell cycle analysis of wt, scramble or miR-100 stably 
expressing BrCSCs determined by propidium iodide staining. * P<0.05. D, representative phase contrast and fluorescence microscopy 
analysis of wt, scramble or miR-100 transduced BrCSCs labelled with PKH-26 and cultured in soft agar up to 40 days. E, flow cytometry 
analysis and quantification of PKH-26 in cells transduced as in (D), after 14 days of culture. The experiments were performed in triplicates. 
** P<0.01.
Figure 2: MiR-100 expression increases upon basal-like Breast Cancer Stem Cell (BrCSC) differentiation. A, miR-
100 expression in BrCSCs derived from human breast tumors evaluated by TaqMan RT-PCR. MiR-100 expression is reported as fold 
changes compared to P1. P1-P4: luminal; P5-P8: basal-like. B, miR-100 expression in basal-like BrCSCs (P5) before and after growth in 
differentiation condition, at the indicated times. Data are representative of two independent experiments.
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Figure 4: MiR-100 affects tumor-initiating ability and inhibits Wnt/β-catenin signaling pathway in BrCSCs. A, in vivo 
growth of BrCSCs expressed as volume of orthotopic tumors generated by fat-pad injection of either wt, scramble or miR-100 expressing 
BrCSCs. Insert: dorsal and ventral whole body in vivo imaging analysis of orthotopic tumor growth. Data are average ± SD of experimental 
groups containing 6 mice. *** P<0.001. B, representative Hematoxylin/Eosin (H&E) and immunohistochemical stainings (Ki67, ALDH1) 
of tumors originated from wt, scramble and miR-100 BrCSCs. Magnification 20x. C, percentage of TOP-GFP positive cells in wt, scramble 
and miR-100 transduced BrCSCs assessed by flow cytometry. As a positive control to monitor β-catenin activity, TOP-GFP reporter 
lentivirus-transduced BrCSCs were treated with Bio (Bio), an inhibitor of GSK-3α/β. D, heat-map showing hierarchical clustering of genes 
in cells transduced as in (A). Gene expression was assessed by using a Wnt target array. E, Percentage of CD10 Max fluorescence intensity 
in scramble or miR-100 expressing BrCSCs, untreated or stimulated either with Wnt3a or DKK1 assessed by flow cytometry. 
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Supplementary Table 1) displaying low levels of miRNAs 
of the miR-100 family (Fig 2A and Supplementary Fig. 
2). These data indicate that miR-100 expression leads to 
the loss of CSC properties such as self-renewal and tumor-
initiating ability.
MiR-100 inhibits the Wnt signaling pathway and 
downregulates Polo-like kinase1 (Plk1)
The Wnt/β-catenin pathway is among the main 
signalling pathways involved in cancer stem cell 
maintenance. Tumor-initiating cells show a constitutive 
activation of this pathway, which can be evaluated by the 
LEF-1/TCF dGFP reporter [31]. In order to investigate 
whether the Wnt pathway contributes to miR-100 pro-
differentiative program, BrCSCs wild type, scramble and 
miR-100 were transduced with the reporter and analyzed 
by flow cytometry. MiR-100 expressing BrCSCs displayed 
a significant reduction of β-catenin activity (Fig. 4C). 
Through gene array analysis, it was observed that miR-
100 leads to inhibition of the Wnt signaling pathway 
and to downregulation of β-catenin target genes (such 
as WISP1/2, DLK1, TCF4 and SFRP2) that control the 
Figure 5: MiR-100 impairs CSC properties by down-regulating Plk1. A, Western blot analysis of Plk1 expression in wt, 
scramble or miR-100 transduced BrCSCs; a total protein lysate of HeLa cells was used as a positive control. B, colony forming efficiency 
of wt and miR-100 expressing BrCSCs transduced with either an empty vector (mock) or Plk1, assessed by soft agar assay; histogram 
shows the quantitative analysis. Data are average + SD of 3 independent experiments. C, representative fluorescence microscopy images 
of BrCSCs transduced as in (B) and labelled with PKH-26 (upper left). Flow cytometry analysis of PKH-26 in cells transduced as in (B) 
after 14 days of culture (bottom left) and the corresponding quantification (right). D, Analysis of BrCSC mortality in bulk and CD49fhigh/
CD24low sorted BrCSCs upon treatment with the Plk1 inhibitor BI2536 (10nM) for 72 hours. The experiments were performed in triplicates. 
UT: untreated.
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balance between stemness and differentiation (Fig. 4D 
and Supplementary Fig. 5). On the contrary, BMP4, 
which promotes terminal differentiation of CSCs [32], 
was upregulated (Fig. 4D and Supplementary Fig. 5). 
To evaluate if the Wnt pathway is epistatic to miR-100 
in controlling breast cancer stemness, we stimulated 
scramble and miR-100 transduced BrCSCs and evaluated 
the expression of the stem cell marker CD10. As shown 
in Figure 4E, in control cells Wnt3a stimulation increased 
the expression of CD10, whereas this effect was no longer 
visible in cells expressing miR-100. Altogether, these 
data infer that miR-100 expression interferes with CSC 
maintenance, acting downstream to the Wnt pathway, and 
triggers the activation of a differentiation program. 
In an attempt to untangle the molecular mechanisms 
underlying miR-100 induced phenotype, the expression 
of Plk1, a known miR-100 target gene recently shown 
to be involved in the regulation of stem cell proliferation 
Figure 6: Ectopic expression of miR-100 reduces stem cell markers and induces markers of differentiation. Flow 
cytometry analysis of CD44, CD24, CD10, CD49f and EpCAM expression in BrCSCs (P5) scramble and stably expressing miR-100. IMC: 
Isotype Matched Control.
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and differentiation [33, 34], was analyzed. MiR-100 
transduced BrCSCs displayed a significant reduction 
of Plk1 protein (Fig. 5A). Rescue experiments were 
performed by re-introducing Plk1 in miR-100 expressing 
BrCSCs and evaluating their self-renewing ability. 
Upon Plk1 expression, colony forming efficiency was 
partially recovered (Fig. 5B), while self-renewal was 
restored at a level comparable to wild type BrCSCs (Fig. 
5C). Consistently, the Plk1 inhibitor BI2536 impaired 
viability both in the bulk population of BrCSCs and in 
the CD49fhigh/CD24low sorted cells (Fig. 5D). These results 
indicate that Plk1 plays a key role in mediating miR-100 
induced phenotype. 
SMARCA5 and SMARCD1, two miR-100 targets 
belonging to the SWI/SNF protein family, have recently 
been shown to participate in differentiation of embryonal 
[24, 35] and cancer stem cells [36]. When we analyzed 
their expression, we found that these two proteins were 
significantly down-regulated in miR-100 transduced 
BrCSCs compared to controls (Supplementary Fig. 6A, 
B), suggesting that SMARC, together with Plk1, reduction 
could contribute to miR-100 dependent differentiation.
Figure 7: Ectopic expression of miR-100 reduces stem cell markers, promotes luminal differentiation and renders 
basal-like BrCSCs responsive to endocrine therapy. A, representative confocal microscopy images of immunofluorescence (IF) 
analysis of ALDH1, Cytokeratins (CK5, CK14, CK8-18) and estrogen receptor (ER) performed in BrCSCs (P5) wt and stably expressing 
either a control scramble or miR-100. Nuclei were counterstained by Toto-3 (blue). Magnification 40x. B, quantification of the IF staining 
shown in (A), performed in three independent replicates. ** P<0.01 *** P<0.001. C, representative FACS analysis of Aldefluor assay 
performed in wt, scramble and miR-100 BrCSCs. Cells were exposed to Aldefluor substrate (BAAA); cells treated with the specific inhibitor 
of ALDH1 (DEAB) are shown in the insert panels and were used to define the population with low and high (gated region) ALDH1 activity. 
D, representative analysis of ER-dependent transcriptional activity. The assay was performed in wt, scramble and miR-100 BrCSCs, non 
transfected (negative control) or transfected (ERE-reporter) with a construct where an Estrogen Responsive Element (ERE) containing 
promoter drives luciferase expression. Luciferase activity was evaluated in the absence or in the presence of 10nM 17-β-estradiol (E2). 
MCF7 cells were used as positive control of response to estradiol. E, Analysis of BrCSC viability upon treatment with tamoxifen (tam) and 
fulvestrant (fulv) at the indicated doses. The experiments were performed in triplicates. ** P<0.01.
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MiR-100 promotes luminal differentiation 
and renders basal-like BrCSCs responsive to 
hormonal therapy
To further validate the role of miR-100 in 
controlling stemness and differentiation of breast 
cancer cells, we evaluated either by flow cytometry or 
immunofluorescence (IF) the expression of putative 
stem/progenitor and differentiation markers upon ectopic 
expression of the miRNA. FACS analysis showed that 
stem cell markers, such as CD44, CD10 and CD49f, were 
drastically reduced, while the differentiation markers 
CD24 and EpCAM increased (Fig. 6). We also assessed 
the expression of additional mammary stem/progenitor 
markers by immunofluorescence analysis. Early 
progenitor/stemness markers such as ALDH1, Cytokeratin 
5 and myoepithelial Cytokeratin 14 were reduced in miR-
100 transduced BrCSCs; conversely, the luminal epithelial 
markers Cytokeratin 8-18 and ER were de novo expressed 
(Fig. 7A, B and Supplementary Fig. 7A, B). Expression 
of ER upon miR-100 transduction was confirmed by 
FACS analysis as well (Supplementary Fig. 8A). Using 
the Aldefluor assay, we found that ALDH1 activity was 
also greatly reduced (Fig. 7C and Supplementary Fig. 
7C). Furthermore, the luminal differentiation promoted 
by miR-100 was observed in CD49fhigh/CD24low sorted 
BrCSCs as well (Supplementary Fig. 8B), confirming that 
miR-100 not only interferes with stemness maintenance, 
but also converts the breast cancer phenotype from basal 
to luminal-like. 
Then, we wondered whether the ER pathway was 
functional in miR-100 expressing BrCSCs. Indeed, cells 
transfected with an ERE luciferase reporter displayed 
an increased luciferase activity in the presence of miR-
100 compared to control cells (Figure 7D). Finally, we 
investigated whether miR-100 expression could sensitize 
basal-like unresponsive BrCSCs to ER inhibitors. 
Viability of miR-100 transduced P5 and P8 BrCSCs was 
significantly affected by tamoxifen and fulvestrant, at 
concentrations comparable to those used as optimal dose 
regimen for the treatment of hormone receptor positive 
breast cancers (Fig. 7E and Supplementary Fig. 7D). 
These findings indicate that the differentiation program 
activated by miR-100 is able to induce ER expression and 
to sensitize basal-like BrCSCs to endocrine therapies.
Low miR-100 expression predicts poor prognosis 
in breast cancer patients 
To understand the clinical relevance of miR-100 as 
a possible prognostic factor, we examined its expression 
in 123 breast tumor specimens. Patients underwent radical 
local-regional therapy for resectable node-negative breast 
cancer and received no further adjuvant treatments until 
relapse (Supplementary Table 2). Patients were categorized 
according to tertiles of miR-100 expression. At a median 
follow-up of 60 months, low miR-100 expression was 
associated with worse distant metastasis-free survival 
in the whole population and in the subgroup with ER-
positive tumors (Fig. 8A). To confirm the prognostic 
value of miR-100, a univariate Kaplan-Meier analysis was 
conducted on two validation sets of breast cancer patients 
who underwent surgery and received adjuvant treatments 
(GEO dataset superSeries GSE22220 and Supplementary 
Table 3). MiR-100 expression could stratify patients 
according to different prognosis (Supplementary Fig. 9) 
in these case series, as well. Moreover, as highlighted 
by Gene Set Enrichment Analysis (GSEA), miR-100 
positively correlated with genes expressed in luminal 
tumors. On the other hand, low levels of the miRNA were 
associated with gene signatures of high-grade, poorly 
differentiated cancers (Fig. 8B). This confirms that low 
miR-100 expression is related to a more undifferentiated 
phenotype.
DISCUSSION
Studies performed over the past years have 
strengthened the hypothesis that breast tumors originate 
from mammary stem cells, as a consequence of 
dysregulation in the usually tightly controlled process of 
self-renewal. Despite the fact that these CSCs represent 
a small percentage of the tumor mass, growing evidence 
points to them as being the cells responsible for the life-
threatening terminal evolution of the disease. They are 
resistant to conventional therapies and can escape anti-
cancer treatments, giving rise to relapse in patients [3, 
4, 37]. Therefore, untangling the molecular mechanisms 
underlying CSC maintenance becomes a priority for the 
development of new cancer therapies able to eradicate the 
disease. 
It is known that miRNAs contribute in sustaining 
stemness of embryonic stem cells, since ESC maintenance 
is hampered by deficiency in the miRNA processing [14]. 
At the same time, miRNAs are essential regulators of 
ESC differentiation, which is associated with changes 
in the expression of specific miRNA patterns [38]. An 
important role of miRNAs in controlling self-renewal and 
differentiation of cancer stem cells has also recently been 
described [15, 39, 40]. 
Breast cancer is a heterogeneous disease which 
includes distinct types of tumors characterized by different 
histological origins, molecular features and prognosis 
[41]. Luminal tumors are characterized at the molecular 
level by the expression of ER and PR receptors. ER and 
PR signaling sustains tumor growth and thus, therapies 
interfering with ER activation are currently the gold 
standard for the treatment of this type of cancer. Basal-
like tumors are defined by their lack of ER, PR and HER2 
expression in about 75% of cases. These cancers are 
poorly differentiated and are loaded with CSCs, a feature 
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that is associated with a poor clinical outcome [28, 42]. 
The absence of the specific molecular targets in basal-like 
breast cancers renders ineffective the targeted therapies 
that significantly improve prognosis for hormone receptor-
positive and HER2-overexpressing breast cancers. 
Therefore, a possible therapeutic strategy to treat basal-
like tumors is to induce CSC differentiation and to allow 
the expression of genes, such as ER, to be used as targets. 
The strategy of using drugs that force malignant cells to 
terminally differentiate has been known for the past thirty 
years as “differentiation therapy” and is strictly connected 
to the concept of tissue-selective therapy [43]. Such an 
approach drastically reduces side effects in patients 
since it avoids indiscriminately killing proliferating cells 
and instead concentrates its efficacy on cancer cells in a 
tissue specific manner, taking advantage of differentiation 
molecules that are specifically expressed in the selected 
tissue. This therapy has its successful paradigm in the 
treatment of acute promyelocytic leukemia (APL) with all-
trans retinoic acid [44]. However, despite the promising 
results obtained in hematological malignancies, the 
application of differentiation therapy in solid tumors 
has been hampered due to inadequate knowledge of 
the mechanisms governing cell differentiation. The 
Figure 8: Low expression of miR-100 correlates with poor prognosis and high grade tumor signatures in breast cancer 
patients. A, Kaplan-Meier curves associated to miR-100 expression in a cohort of 123 breast cancer patients (for characteristics of patients 
see Supplementary Table 2). Left panel: all patients; right panel: estrogen receptor-positive patients. B, miR-100 expression was correlated 
with gene expression data and gene set enrichment analysis was performed on ranked genes. Two of the top positively (left) or negatively 
(right) correlated gene sets are reported.
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current findings uncover miR-100 as a key player in the 
complex scenario of the differentiation process. They 
show that miR-100 is critical in controlling stemness and 
differentiation of patient-derived basal-like breast CSCs. 
MiR-100 interferes with the CSC properties, impairing 
self-renewal and blocking tumor-initiating ability. 
Our results also suggest that miR-100 induces a pro-
differentiative program which involves the Wnt/β-catenin 
pathway. Activation of β-catenin and expression of Wnt 
target genes are involved in the balance between stemness 
and differentiation. Indeed, it was found that Wnt pathway 
activation was reduced in cells expressing miR-100 and 
Wnt3a treatment was unable to promote the expression of 
stem cell markers. Moreover, the down-regulation of Plk1, 
a serine/threonine kinase target of miR-100 that controls 
cell cycle progression, was observed. Recently, Plk1 has 
been implicated in the regulation of stem cell maintenance 
and proliferation, as inhibiting Plk1 activity impaired 
growth and induced apoptosis of neurospheres [34] and 
of colon cancer initiating cells [33]. Here it was shown 
that Plk1 is required to sustain expansion of BrCSCs, as 
miR-100 mediated down-regulation of Plk1impairs CSC 
properties and depletes the CSC pool. 
Furthermore data from this research provide 
evidence that the exogenous expression of this miRNA 
not only hampers the replication potential of basal-like 
BrCSCs, but also induces their differentiation toward 
a luminal phenotype. In this way, miR-100 allows the 
conversion of an aggressive molecular subtype of cancer 
into a subtype with a better prognosis, for which effective 
treatments are available. Indeed, miR-100 promoted 
the expression of the estrogen receptor and rendered 
basal-like cells responsive to 17-β-estradiol and to the 
anti-proliferative activity of tamoxifen and fulvestrant. 
Several miRNAs (such as miR-206, miR-221/222, miR-
22, miR-17/92 and miR-145) inhibit ER expression and 
sustain resistance to hormonal therapies [45-47]. However, 
miRNAs that are able to induce de novo expression of this 
target molecule and responsiveness to endocrine treatment 
in triple negative breast cancer cells have never been 
previously described. 
The results obtained in this pre-clinical system are 
consistent with the analysis performed on breast tumor 
specimens. High levels of miR-100 are associated with 
luminal gene signatures, while undifferentiated high 
grade tumors correlate with lower miRNA expression. 
This is also in line with recent findings that demonstrate 
the presence of a higher CSC content in G3 poorly 
differentiated tumors [30]. This could explain the poor 
outcome and the tendency to relapse [28]. Moreover, the 
analysis of breast tumor specimens from two validation 
data sets, which include patients who received adjuvant 
therapy, revealed that low expression of miR-100 
correlates with a negative prognosis in ER-positive 
patients. This raises the question as to whether this miRNA 
might be a predictor of hormonal therapy response. Further 
studies on appropriate cohorts of patients are warranted to 
address this hypothesis. 
Overall, these findings have relevant clinical 
implications, as they suggest the possibility of targeting 
basal-like CSCs using a pro-differentiative therapy 
approach, by promoting miR-100 expression. Moreover, 
they propose miR-100 as a response predictor to endocrine 
therapy and offer a therapeutic perspective in treating an 
aggressive tumor type, for which there are no effective 
therapeutic options available at this time.
METHODS
Tissue collection and cell culture 
Fresh tissue acquired from mastectomies of 8 
patients (age 40–89) were collected at the University 
of Palermo and Fondazione IRCCS INT of Milan, in 
accordance with ethical standards. Breast tumor cells 
were purified from fresh tissue via enzymatic digestion 
as previously described [48]. Thereafter, single cell 
suspensions were plated in ultra-low attachment flasks 
(Corning) at a density of 1×105/ml and grown in a medium 
supplemented with bFGF (10 ng/ml, Sigma) and EGF 
(20 ng/ml, Sigma). To induce differentiation, cells were 
cultured in adherent conditions in Ham’s/F-12 medium 
(Euroclone), supplemented with 5% fetal bovine serum 
(FBS), insulin (25μg/ml, Sigma) and hydrocortisone (1mg/
ml, Sigma). MCF7 cells were purchased from ATCC and 
cultured in DMEM supplemented with 10% fetal bovine 
serum (Sigma). 
Cell transfection, lentiviral constructs and cell 
transduction
MCF7 cells were transiently transfected with a miR-
100 specific antagomir (AM10188, Ambion) in serum free 
medium using Lipofectamine 2000 (Invitrogen). MiR-100 
stable expression was obtained by transducing cells with 
a lentivirus expressing miR-100 as previously described 
[26]. The lentiviral short hairpin scramble (pLKO.1) 
used as a control was purchased from Sigma. For the 
in vivo imaging, gene transfer was performed using a 
TWEEN lentiviral vector containing luciferase (LUC) 
and green fluorescent protein (GFP) as reporter genes. For 
β-catenin activity assay, BRCSCs were transduced with 
lentiviral-TOP-dGFP-reporter (Addgene) that consists of 
a LEF-1/TCF-responsive promoter upstream d2-eGFP. 
Transfection of packaging cell line HEK-293T was 
performed using FuGENE Reagent (Roche) and following 
the manufacturer’s instructions. BRCSCs were dissociated 
into single cells, then infected with 100 ng virus/105 cells.
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Biological assays
For the clonogenic assay, cells were plated on a 
ultra-low adhesion 96-well plate at a concentration of 
a single cell per well and observed for 21 days. Wells 
containing either none or more than one cell were 
excluded from the analysis. For soft agar assay, 0.4% 
Seaplaque soft agar (Lonza) was diluted with stem cell 
medium and was covered by a second 0.3% soft agar layer 
in which BrCSCs were embedded. After 21 days, colonies 
were stained with 0.005% crystal violet (Sigma) for 1 hour 
at 37°C. For anti-estrogen treatment, cells were treated 
with 2.5-10 μM tamoxifen (Selleckchem) and 0.5-2 μM 
fulvestrant (Selleckchem) for 24-48 hours. Cell viability 
was assessed by means of a cell Titer Aqueous Assay Kit 
(Promega) following the manufacturer’s instructions. 
Alternatively, cell death was evaluated by orange acridine/
ethidium bromide staining as previously described [48] 
and using Cell Titer-Glo luminescent cell viability assay 
kit (Promega). For the assessment of apoptosis, 3x103 
cells/well were seeded in ultra-low adhesion 96-well 
plate in stem cell medium and activation of caspases 3 
and 7 was evaluated after 72hours using the Caspase-
Glo 3/7 Assay (Promega). The proliferative rate of stem 
cells was analyzed using the PKH-26 assay (2×10-6 M, 
Sigma) according to manufacturer’s instructions. Samples 
were analyzed by FACSCalibur (BD Biosciences). For 
β-catenin activity experiments, cells transduced with the 
indicated lentiviral constructs were analyzed by FACS. 
As a positive control, cells were treated with BIO (1uM, 
Calbiochem) for 24 hours in order to inhibit GSK-3α/β. 
For viability assay, single cells suspensions were treated 
with the Plk1 inhibitor BI2536 (10nM, Selleckchem) for 
72 hours.
In order to evaluate changes of CD10 expression 
upon Wnt pathway modulation, scramble or miR-100 
BrCSCs were treated either with Wnt3a (300ng /ml) every 
6 hours for 24 hours or DKK1 (200ng/ml) for 24 hours 
and then analyzed by flow cytometry.
FACS analysis and Cell sorting
BrCSCs were exposed to primary antibodies CD44 
(BU75, Ancell), CD24 (ML5, R&D System), CD10 
(FR4D11, Santa Cruz Biotechnology), CD49f (GoH3 
Miltenyi Biotec), EpCAM (AF960, R&D System) or 
corresponding isotype controls, rinsed and labeled with 
secondary antibodies. BrCSCs were stained with CD49f 
and CD24 and successively sorted via flow cytometry 
using an FACSAria cell sorter (BD Biosciences). The 
analysis of ALDH1 activity was performed using the 
ALDEFLUOR kit (StemCell Technologies). For cell cycle 
analysis, BrCSCs were fixed in 70% ethanol and incubated 
with 50 μg/mL propidium iodide (Sigma-Aldrich), 3.8 
mmol/L sodium citrate (Sigma) and 10 μg/mL RNase 
(Sigma). Samples were analyzed by FACSCalibur and 
CellQuest Software (BD Biosciences). 
Quantitative analysis of microRNA and gene 
expression
Total RNA was extracted using TRI Reagent 
solution (Ambion) following manufacturer’s instructions. 
Analysis of miR-100, miR-99a and miR-99b was 
performed starting from equal amounts of total RNA/
sample (10ng) using the specific Taqman microRNA 
assay kits (Applied Biosystems). MiRNA expression was 
calculated as fold change using the delta-delta CT method 
and RNU48 as endogenous control.
Gene expression was evaluated by quantitative real-
time PCR using the EXPRESS SYBR green (Invitrogen). 
Retrotranscription was performed using the High Capacity 
Retrotranscription Kit (Applied Biosystems) starting from 
500ng of total RNA.
Expression profiling of pluripotency genes was 
performed starting from 1.5ug of total RNA using 
TaqMan Human Stem Cell Pluripotency Arrays (Applied 
Biosystems), according to manufacturer’s instructions. 
Gene expression was calculated as ∆CT (CT gene - CT 
GAPDH). The differentially expressed genes were 
statistically analyzed using t-test and genes with a P<0.05 
were included in the heat-map. Expression was reported 
as -∆CT normalized to the median. The heat-map was 
obtained by Gedas software [49].
Expression of Wnt target genes was performed 
through RT2 profiler PCR array (PAHS-243, Qiagen), 
according to manufacturers’ instructions. Arrays were 
performed independently for BrCSCs wt, scamble and 
miR-100 and at least 3 technical replicates were run for 
each sample. Cycle threshold values were normalized 
using the average of 5 housekeeping genes on the same 
array (B2M, HPRT1, RPL13A, GAPDH and actin B). The 
comparative cycle threshold method was used to calculate 
the relative quantification of gene expression.
Animal models
Orthotopic xenografts were obtained by injecting 
105 BrCSCs P5 or P8 in the murine mammary gland of 
three week-old female NOD/SCID mice. In vivo imaging 
was performed by a Biospace instrument upon i.p. 
injection of Luciferin (150 mg/kg, Promega). 
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded sections and labelled with Ki67 (MIB-1, Dako) 
and ALDH1 (44, BD Biosciences). Immunocomplexes 
were revealed by peroxidase labeled streptavidin following 
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manufacturer’s instructions (LSAB2, Dako). Stainings 
were revealed using AEC (Dako) and counterstained with 
aqueous hematoxylin. 
Immunofluorescence
BrCSCs were fixed with 2% paraformaldehyde 
for 30 minutes at 37°C and incubated O.N. at 4°C with 
the following primary antibodies: ALDH1 (44, BD), 
CK5 (XM26, Novocastra), CK14 (LL002, Novocastra), 
CK8-18 (CD10, Novocastra), MUC1 (BD Pharmigen), 
VIMENTIN (R28, Cell Signaling), ER (6F11, 
Novocastra). Thereafter, cells were labeled with secondary 
antibodies (Invitrogen). Nuclei were counterstained with 
Toto-3 (Invitrogen).
Western blot
Cell pellets were lysed in buffer (TPER, Pierce; 300 
mM NaCl; 1 mM orthovanadate; 200 mM PEFABLOC, 
Roche; 5 µg/ml Aprotinin, 5 µg/ml Pepstatin A, 5 µg/ml 
Leupeptin, Sigma). Lysates (30 µg/lane) were fractioned 
with SDS-PAGE and blotted to PVDF. Membranes were 
blocked with no-fat dry milk in TBS 0.05% Tween20 and 
incubated overnight with a specific antibody for Plk1 
(208G4, Cell Signaling), SMARCD1 (AB81621, Abcam), 
SMARCA5 (MAB120, Millipore) and β-actin (JLA20, 
Calbiochem). Densitometric analysis was performed by 
UVP. 
ERE-reporter assay
Cells were transfected with 1μg mixture of an 
inducible ERE-responsive firefly luciferase construct 
(kindly provided by Dr. De Bortoli, University of 
Torino) and a constitutively expressing Renilla luciferase 
construct (40:1) (Cignal Reporter Assay, Qiagen) using 
Lipofectamine 3000 reagent (Life Technologies) according 
to the manufacturer’s instructions. Cells were seeded into 
ultra-low attachment 24 wells plates (Corning) at a density 
of 100,000 cells per well. After 48 hours from transfection, 
cells were treated for 6 hours with either vehicle or 10 nM 
17-β-Estradiol (E2758, Sigma) and the reporter activity 
was measured by luminescence. Values were normalized 
to Renilla luciferase activity; data are presented as relative 
luciferase values. 
Case series at INT 
The case series collected at INT in Milan consisted 
of 123 patients with primary invasive breast cancer and 
negative lymph nodes. They were subjected to radical and/
or conservative surgery, plus radiotherapy. These patients, 
recruited from 1990 to 1998, were identified among 
those who developed distant metastasis within 5 years of 
treatment (59 patients, disease free survival range: 8-58 
months) and those who were disease-free for more than 
60 months (64 patients, disease free survival range: 60-
185 months). The two subsets of patients were comparable 
in age, tumor size, histotype, ER and HER2 status. Each 
patient wrote an informed consent, which authorized 
the use of material for research purposes. The study was 
approved by the Independent Ethics Committee and the 
Institutional Review Board. 
miRNA and gene expression analysis in breast 
cancer patients
Global gene and miRNA expression data were 
obtained using the HumanRef-6_v3 and Human miRNA_
V2 Illumina BeadChips, respectively. Raw data were 
generated using the Illumina BeadStudio 3.8 software and 
processed using the Bioconductor lumi package. After 
quality control, the Robust Spline Normalization was 
applied. For gene signature expression analysis, all genes 
were correlated with miR-100 expression and gene sets 
from the C2 collection of the MSigDB were tested for 
their enrichment among positively or negatively correlated 
genes using GSEA (http://www.broadinstitute.org/gsea).
Statistical analysis
Data were expressed as average ± standard 
deviation. Statistical significance was determined by the 
t-test or by Analysis of Variance (one-way or two-way) 
with Bonferroni post-test. P values <0.05 were considered 
significant (* P<0.05; ** P<0.01; *** P<0.001).
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